Effects of erythropoietin after an acute myocardial infarction: Rationale and study design of a prospective, randomized, clinical trial (HEBE III)

Background Preclinical studies have consistently shown that erythropoietin (EPO), administered after an acute myocardial infarction (AMI), reduces infarct size and improves left ventricular function. Furthermore, EPO promotes endothelial progenitor cell growth, which increases angiogenesis. A recent...

Full description

Saved in:
Bibliographic Details
Published in:The American heart journal 2008-05, Vol.155 (5), p.817-822
Main Authors: Belonje, Anne M., MD, Voors, Adriaan A., MD, PhD, van Gilst, Wiek H., PhD, Anker, Stefan D., MD, PhD, Slart, Riemer H., MD, PhD, Tio, Rene A., MD, PhD, Zijlstra, Felix, MD, PhD, van Veldhuisen, Dirk J., MD, PhD
Format: Article
Language:English
Subjects:
Angioplasty, Balloon, Coronary
Biological and medical sciences
Blood pressure
Cardiology. Vascular system
Cardiovascular
Coronary heart disease
Erythropoietin - administration & dosage
Female
Heart
Heart attacks
Heart rate
Hematinics - administration & dosage
Humans
Informed consent
Ischemia
Male
Medical imaging
Medical sciences
Myocardial Infarction - diagnostic imaging
Myocardial Infarction - drug therapy
Myocarditis. Cardiomyopathies
Radionuclide Ventriculography
Stroke Volume - drug effects
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Preclinical studies have consistently shown that erythropoietin (EPO), administered after an acute myocardial infarction (AMI), reduces infarct size and improves left ventricular function. Furthermore, EPO promotes endothelial progenitor cell growth, which increases angiogenesis. A recent pilot study in patients with AMI suggested that a single bolus of EPO was safe and well tolerated. Methods The HEBE III is a multicenter, prospective, randomized, open-label trial with blinded evaluation of the primary end point. The primary objective is to study the effect on left ventricular ejection fraction (LVEF) of a single bolus of EPO, administered directly after a primary percutaneous coronary intervention (PCI) for a first AMI. A total of 466 patients with thrombolysis in myocardial infarction 0/1 flow before the PCI procedure and 2/3 flow after a successful PCI are randomly assigned to either receive standard medical care or a single bolus with 60,000 IU of EPO on top of standard medical care within 3 hours of the PCI procedure. Primary end point of the study is LVEF after 6 weeks, assessed by planar radionuclide ventriculography. Implications If an improvement of LVEF with a single bolus of EPO is demonstrated, this simple approach might further improve clinical outcome of patients with AMI.
ISSN:0002-8703
1097-6744
DOI:10.1016/j.ahj.2007.12.036